Literature DB >> 25849845

Effect of arsenite on nitrosative stress in human breast cancer cells and its modulation by flavonoids.

Elio A Soria1, Guillermina A Bongiovanni, Cintia Díaz Luján, Aldo R Eynard.   

Abstract

Arsenic (As) is used in the treatment of leukemia and breast cancer due to its oxidative cytotoxic action. However, it is also toxic to normal cells. One proposed anticancer mechanism induced by As might be nitrosative stress (NS). It is believed that antioxidant flavonoids in combination with As might reduce its toxic action on normal cells without interfering with its antitumor action. In the present study, we evaluated the antineoplastic potential of As on breast human cancer lines MCF-7 and ZR-75-1 treated with redox-modulating flavonoids, such as quercetin (Q) and silymarin (S). Even though both cell lines differed about their oxidative responsiveness, their viability was decreased by NS induction through γ-glutamyltranspeptidase inhibition. Arsenic triggered NS in both MCF-7 and ZR-75-1 cultures, with the formers more sensitive without recovering their pre-treatment capacity. ZR-75-1 cells maintained their antioxidant status, whereas MCF-7 ones treated with S, As, and As + Q did not. Silymarin did not interfere with the described As bioactivity. NS was an anticancer mechanism exerted by As depending on the redox cellular response that could be differentially modified by dietary antioxidants. Hence, it is worthwhile to consider the use of dietary antioxidants as adjuvant in cancer chemotherapy, especially when using As.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25849845     DOI: 10.1080/01635581.2015.1019637

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  2 in total

1.  Sustainable and efficient protocols for in vitro germination and antioxidants production from seeds of the endangered species Araucaria araucana.

Authors:  María C Gallia; Julieta Echeverri Del Sarto; Guillermina A Bongiovanni
Journal:  J Genet Eng Biotechnol       Date:  2021-12-09

2.  Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.

Authors:  Xiao Yu Wu; Hao Xu; Zhen Feng Wu; Che Chen; Jia Yun Liu; Guan Nan Wu; Xue Quan Yao; Fu Kun Liu; Gang Li; Liang Shen
Journal:  Oncotarget       Date:  2015-12-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.